Business
Apyx Medical Corporation Announces Proposed Public Offering of Common Stock
CLEARWATER Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as
About this update from Apyx Medical Corporation
[{"type":"image","alt":"Apyx Medical Corporation","displaySize":"","headline":null,"caption":"Apyx Medical Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/f776ee7f25241f6a4c93b21ba8aff893"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WNW7RVUw1wUG.ea_dTVO0Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f776ee7f25241f6a4c93b21ba8aff893","width":300,"height":157}},"lazy":false},{"type":"text","content":"CLEARWATER Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.","length":545,"tagName":"p"},{"type":"text","content":"Lucid Capital Markets is acting as the sole book-running manager for the offering.","length":82,"tagName":"p"},{"type":"text","content":"The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-268532) filed with the Securities and Exchange Commission (“SEC”) on November 22, 2022, and declared effective by the SEC on December 2, 2022.","length":238,"tagName":"p"},{"type":"text","content":"A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained by contacting Lucid Capital Markets, LLC, 570 Lexington Avenue, 40th Floor, New York, NY 10022.","length":409,"tagName":"p"},{"type":"text","content":"This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such sta...